Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone and exercise for hypertensive response to exercise with abnormal LV filling
ACTRN12609000835246Phase 4Completed
- Sponsor
- The University of Queensland
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of spironolactone in hypertension (HTN) and left ventricular diastolic dysfunction (LVDD), sponsored by The University of Queensland. Primary endpoint: Reduction of fibrosis assessed by backscatter and strain markers. Started Sep 2006; status: completed.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)left ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on ACTRN12609000835246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000835246.